At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRA Mira Pharma
Market Closed 12-20 16:00:00 EST
1.06
+0.06
+6.00%
盘后1.09
+0.03+2.83%
19:58 EST
High1.09
Low1.00
Vol389.67K
Open1.02
D1 Closing1.00
Amplitude9.00%
Mkt Cap17.55M
Tradable Cap11.20M
Total Shares16.56M
T/O412.01K
T/O Rate3.69%
Tradable Shares10.57M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
MIRA Pharmaceuticals submits IND to FDA for Ketamir-2
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.